

Partial Molar Pregnancy with Extreme Elevation of Quantitative β -hCG: A Clinical and Laboratory Outlier

Zachary Franklin, MS1, Amanda Royek, MS2, Kaitlyn Vu, MS1, Anthony Royek, MD3

1. Mercer University School of Medicine, 2. Albert Einstein School of Medicine, 3. Memorial Health University Medical Center,
Department of Obstetrics and Gynecology

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.

Disclosures

We have no financial disclosures for any authors or conflicts of interest related to this study.

Background

- Gestational trophoblastic disease (GTD)
- A hydatidiform mole is a type of GTD, further classified as partial or complete.
- Partial molar pregnancies: fertilization of a haploid egg by two sperm or a diploid sperm
- Typically resulting in fetal triploid karyotypes of 69XXX, 69XXY, or 69XYY (1).
- Incidence of complete molar pregnancies of 1-3 per 1000 pregnancies and partial molar pregnancies of 3 per 1000 pregnancies in high-income countries (2).




Figure 1 - A comparison between Complete Molar vs. Partial Molar Pregnancy genetic fertilization. (Duffy L, et al. 2015)

Risk Factors

Risk factors for complete molar pregnancies include:

- maternal age less than 15 years or over 40 years
- previous miscarriage
- Asian ethnicity
- prior history of molar pregnancy

Partial molar pregnancies are less associated with extremes of age but are associated with:

- prior miscarriages
- long-term OCP use
- prior molar pregnancies

Complications

- Choriocarcinoma, which occurs in 1 in 40,000 pregnancies and develops in 0.5% of partial molar pregnancies (3).
- Post evacuation of the placenta, long term surveillance of β -hCG levels is necessary


Background & Objective

- Most GTD cases present with quantitative β -hCG levels between 50,000 - 100,000 mIU/mL, with high β -hCG levels more associated with complete molar pregnancies (4).
- Our case describes a partial molar pregnancy with a β -hCG level over 2,000,000 mIU/mL with pre-eclampsia signs and symptoms.

Case Presentation

- 29y/o F, G2P1001 at 16 weeks EGA, referred to the high-risk MFM clinic due to a suspected placental abnormality
- The patient reported intermittent vaginal bleeding for two weeks, worsening mid-thigh and lower extremity edema, shortness of breath, and a 38 lb weight gain during the pregnancy
- Blood pressures were elevated at 161/109 and 159/118, pulse 112 bpm. Ultrasound revealed placentomegaly with hydrops and a fetus measuring 131 g, 22nd percentile for gestational age with a suspected cardiac anomaly. Evaluation of complete fetal anatomy was limited due to fetal position and early gestational age
- Labs revealed a β -hCG of 2,247,800 mIU/m, TSH <0.02 mIU/L, and free T4 1.35 ng/dL. Interestingly, NIPT was negative for fetal aneuploidy, with a fetal fraction of 15%, female sex predicted

Partial molar pregnancy at 16 weeks EGA



Partial molar pregnancy at 16 weeks EGA



Case Presentation

- Given the extremely elevated β -hCG level, hypertension, symptoms and ultrasound findings, partial molar pregnancy was considered most likely, with the possibility of an abnormal twin placenta pregnancy in the differential.
- The patient was appropriately counseled and agreed to proceed with termination of pregnancy by dilation and evacuation procedure.
- During laminaria placement brisk cervical bleeding was encountered, prompting an urgent though uncomplicated dilation and evacuation procedure under ultrasound guidance.
- Postoperatively, the patient received IV magnesium sulfate, PO labetalol and IV furosemide.

Case Presentation

- The patient had a 6 L diuresis and a 7 lb weight loss over 24 hours and her condition improved markedly thereafter. A chest x-ray performed was negative for lesions and pulmonary edema. On postoperative day 2 the β -hCG was 170,640 mIU/mL.
- The patient was discharged on oral labetalol and oral furosemide with plans for long-term β -hCG monitoring and contraception for 6-12 months. β -hCG levels declined to below 5 mIU/mL after 2 months and remained negative at 4 months.
- Tissue pathology confirmed edematous hydropic villi and fetal tissue consistent with a partial molar pregnancy.
- FISH revealed a DOUBLE TRISOMIC signal pattern for chromosomes 1 and 11 in 19/50 nuclei consistent with TRIPLOIDY - clinically associated with partial hydatidiform molar gestation.

Labs & β -hCG Over Time

Labs	Values
β -hCG	2,272,500
Blood Pressure	161/109
Pulse	112
TSH	<0.02
T4	1.35




Figure 2. Table: Serum β -hCG levels, blood pressure, pulse, TSH and T4 levels at initial presentation.

Graph: Serum β -hCG levels over time at initial presentation, 4 hours, 48 hours, 6, 12, 25, and 35 days.

Figure and table created using Microsoft PowerPoint and Excel.

Treatment & Management

- Management: Earlier detection by ultrasound has allowed for changes in clinical presentation and decreased morbidity from uterine evacuation.
- Long term monitoring of β -hCG is essential for early diagnosis of gestational trophoblastic neoplasia (GTN). (2)





Figure 3 – Complete Molar Pregnancy histology (left) (Jagtap S, et al. 2017).
Ultrasound (right) (Soper. 2021)




Figure 4 – Partial Molar Pregnancy histology (left) (Jagtap S, et al. 2017).
Ultrasound (right) (Abddi A, et al. 2013)

Conclusion

- This case highlights a rare presentation of partial molar pregnancy with extremely elevated β -hCG levels and preeclampsia.
- Prompt diagnosis by ultrasound and β -hCG evaluation, uterine evacuation and confirmatory histopathology are essential for satisfactory maternal outcomes.

Acknowledgements

Special thanks to Dr. Anthony Royek, Kaitlyn Vu, and Amanda Royek for their guidance and contributions.

Thank you to the Memorial Health University Medical Center Department of Obstetrics and Gynecology and Mercer University School of Medicine for their support.

References

1. Soper, J. Gestational Trophoblastic Disease: Current Evaluation and Management. *Obstetrics & Gynecology* 2021; 137(2): 355-370. DOI: 10.1097/AOG.0000000000004240.
2. Ngan H, Seckl M, Berkowitz R, et al. Update on the diagnosis and management of gestational trophoblastic disease. *International Journal of Gynecology & Obstetrics*. 2018; 143: 79-85. doi: 10.1002/ijgo.12615.
3. Duffy L, Zhang L, Sheath K, Love D, George A. The Diagnosis of Choriocarcinoma in Molar Pregnancies: A Revised Approach in Clinical Testing. *J Clin Med Res*. 2015;7(12):961-6. doi: 10.14740/jocmr2236w.
4. Jagtap S, Aher V, Gadhiya S, Jagtap S. Gestational Trophoblastic Disease - Clinicopathological Study at Tertiary Care Hospital. *J Clin Diagn Res*. 2017;11(8):EC27-EC30. doi: 10.7860/JCDR/2017/27232.10458.
5. Abdi A, Stacy S, Mailhot T, Perera P. Ultrasound detection of a molar pregnancy in the emergency department. *West J Emerg Med*. 2013 Mar;14(2):121-2. doi: 10.5811/westjem.2012.7.12994. PMID: 23599844; PMCID: PMC3628456.